SLDB

Solid Biosciences Inc.

Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. DE · CIK 0001707502
$7.14 -1.11% $702.9M
Insider Selling Cluster (7 insiders)High Impact Filing (7/10)15 New Institutional Positions3 Institutional Exits
Vol
Market Cap$702.9M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (95%)
Inst. Holders50 funds
Inst. Value$334.2M
Inst. Activity15 buys / 3 sells
Insider Activity0B / 13S
Insider Net $-$2.3M
SEC Reports5
Press Releases5
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001707502·Prev Close $7.22

Recent Activity

Jun 10, 2026 Insider
Stone Adam Leo was granted 77,500 shares
Director
Jun 10, 2026 Insider
Ganot Ilan was granted 77,500 shares
Director
Jun 10, 2026 Insider
Keresty Georgia was granted 77,500 shares
Director
Jun 1, 2026 other
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (th
May 12, 2026 SEC
Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net loss widening to $5
PRESS-RELEASE — Impact 6/10
May 7, 2026 Press
Solid Biosciences dosed the first participant in its Phase 3 IMPACT DUCHENNE trial for SGT-003, a gene therapy for Duche
Impact 7/10
Apr 23, 2026 SEC
Solid Biosciences is holding its 2026 annual meeting with several key proposals, including the ratification of Ilan Gano
DEFA14A — Impact 3/10
Apr 10, 2026 SEC
Solid Biosciences Inc. announced a board seat reclassification for director Ilan Ganot, who resigned from Class III and
8-K — Impact 2/10

Price Targets

$17.38 +143.5% upside Strong Buy
Current $7.14 Low $11.00 Median $16.00 High $26.00 13 analysts
$11.00 $26.00

Analyst Ratings

Strong Buy95% buy · 20 analysts
8Strong Buy
11Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Jun 3, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy
May 18, 2026 Wedbush REITERATE Outperform → Outperform
May 13, 2026 Wedbush MAINTAIN Outperform → Outperform
May 13, 2026 Piper Sandler MAINTAIN Overweight → Overweight
Mar 25, 2026 JP Morgan MAINTAIN Overweight → Overweight

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.46 $-0.56 — $-0.36 -10% YoY 13
Next Q $-0.48 $-0.57 — $-0.39 1% YoY 13
Current FY $-1.96 $-2.51 — $-1.67 2% YoY 13
Next FY $-1.96 $-2.33 — $-1.56 -0% YoY 12

Latest Reports

BEARISH PRESS-RELEASE 6/10
Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net loss widening to $5
May 12, 2026
BULLISH Press 7/10
Solid Biosciences dosed the first participant in its Phase 3 IMPACT DUCHENNE trial for SGT-003, a gene therapy for Duche
May 7, 2026
NEUTRAL DEFA14A 3/10
Solid Biosciences is holding its 2026 annual meeting with several key proposals, including the ratification of Ilan Gano
Apr 23, 2026

Top Institutional Holders

FundValueMove
RA CAPITAL MANAGEMENT, L.P.$67.2MADD
BlackRock, Inc.$35.7M—
JANUS HENDERSON GROUP PLC$28.9MNEW
FMR LLC$26.0MADD
VANGUARD CAPITAL MANAGEMENT LLC$19.3M—

Recent Insider Trades

DateInsiderTypeValue
Jun 10, 2026Stone AdamA$0.00
Jun 10, 2026Ganot IlanA$0.00
Jun 10, 2026Keresty GeorgiaA$0.00
Jun 10, 2026Kahn ClareA$0.00
Jun 10, 2026Sullivan LynneA$0.00
50 institutional holders with $334.2M total value (46,448,109 shares) as of 2026-Q1. Top holders: RA, BlackRock,, JANUS. Net buying activity: 15 institutions added/increased vs 3 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1RA CAPITAL MANAGEMENT, L.P.9,339,978$67.2M20.1%ADD +60.7%
2BlackRock, Inc.4,958,354$35.7M10.7%—
3JANUS HENDERSON GROUP PLC4,010,695$28.9M8.6%NEW
4FMR LLC3,606,404$26.0M7.8%ADD +77.7%
5VANGUARD CAPITAL MANAGEMENT LLC2,674,624$19.3M5.8%—
6CITADEL ADVISORS LLC2,596,800$18.7M5.6%—
7AMERIPRISE FINANCIAL INC2,438,849$17.6M5.3%NEW
8Alyeska Investment Group, L.P.2,280,125$16.4M4.9%ADD +35.5%
9FRANKLIN RESOURCES INC2,192,937$15.8M4.7%ADD +37.1%
10Point72 Asset Management, L.P.2,050,843$14.8M4.4%ADD +81.3%
11ADAGE CAPITAL PARTNERS GP, L.L.C.1,756,506$12.6M3.8%ADD +25.5%
12STATE STREET CORP1,125,487$8.1M2.4%—
13DIMENSIONAL FUND ADVISORS LP956,135$6.9M2.1%ADD +40.8%
14GOLDMAN SACHS GROUP INC935,535$6.7M2.0%—
15BLAIR WILLIAM & CO/IL651,216$4.7M1.4%—
16Woodline Partners LP495,076$3.6M1.1%ADD +56.3%
17Nuveen, LLC400,292$2.9M0.9%—
18BANK OF AMERICA CORP /DE/386,793$2.8M0.8%TRIM -56.4%
19Invesco Ltd.340,940$2.5M0.7%DOUBLED +124.1%
20VANGUARD PORTFOLIO MANAGEMENT LLC338,630$2.4M0.7%—

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
RA CAPITAL MANAGEMENT, L.P.ADD5,811,4239,339,978+60.7%$67.2M2026-Q1
JANUS HENDERSON GROUP PLCNEW—4,010,695—$28.9M2026-Q1
FMR LLCADD2,029,8983,606,404+77.7%$26.0M2026-Q1
AMERIPRISE FINANCIAL INCNEW—2,438,849—$17.6M2026-Q1
Alyeska Investment Group, L.P.ADD1,682,8052,280,125+35.5%$16.4M2026-Q1
FRANKLIN RESOURCES INCADD1,599,2332,192,937+37.1%$15.8M2026-Q1
ADAGE CAPITAL PARTNERS GP, L.L.C.ADD1,400,0001,756,506+25.5%$12.6M2026-Q1
DIMENSIONAL FUND ADVISORS LPADD679,084956,135+40.8%$6.9M2026-Q1
Woodline Partners LPADD316,823495,076+56.3%$3.6M2026-Q1
Invesco Ltd.DOUBLED152,126340,940+124.1%$2.5M2026-Q1
MORGAN STANLEYTRIM394,266261,130-33.8%$1.9M2026-Q1
BALYASNY ASSET MANAGEMENT L.P.TRIM360,937178,253-50.6%$1.2M2026-Q1
RENAISSANCE TECHNOLOGIES LLCDOUBLED52,800124,272+135.4%$894.8K2026-Q1
PANAGORA ASSET MANAGEMENT INCTRIM226,75591,095-59.8%$655.9K2026-Q1
STATE OF WISCONSIN INVESTMENT BOARDADD30,00745,607+52.0%$328.4K2026-Q1
HSBC HOLDINGS PLCADD22,15139,511+78.4%$284.5K2026-Q1
Rockefeller Capital Management L.P.DOUBLED3442,589+652.6%$18.6K2026-Q1
HRT FINANCIAL LPDOUBLED14,91986,905+482.5%$625.002026-Q1
Point72 Asset Management, L.P.ADD1,333,0052,416,108+81.3%$13.6M2025-Q4
FMR LLCTRIM2,914,1272,029,898-30.3%$11.4M2025-Q4
ADAGE CAPITAL PARTNERS GP, L.L.C.TRIM4,000,0001,400,000-65.0%$7.9M2025-Q4
DIMENSIONAL FUND ADVISORS LPADD443,541679,084+53.1%$3.8M2025-Q4
MORGAN STANLEYADD257,846394,266+52.9%$2.2M2025-Q4
BALYASNY ASSET MANAGEMENT L.P.TRIM732,608360,937-50.7%$2.0M2025-Q4
BANK OF AMERICA CORP /DE/TRIM789,996344,294-56.4%$1.9M2025-Q4
15 unique insiders with 50 transactions. Net insider value: -$2.3M ($0.00 bought, $2.3M sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 10, 2026Stone Adam LeoDirectorAWARD77,500——
Jun 10, 2026Ganot IlanDirectorAWARD77,500——
Jun 10, 2026Keresty GeorgiaDirectorAWARD77,500——
Jun 10, 2026Kahn ClareDirectorAWARD77,500——
Jun 10, 2026Sullivan Lynne MarieDirectorAWARD77,500——
Jun 10, 2026PERCEPTIVE ADVISORS LLCDirectorAWARD77,500——
Jun 10, 2026Nagendran SukumarDirectorAWARD77,500——
Jun 10, 2026SMITH IAN FDirectorAWARD77,500——
Jun 10, 2026Freed Martin IDirectorAWARD77,500——
Apr 2, 2026SMITH IAN FDirectorEXERCISE3,441——
Mar 9, 2026PERCEPTIVE ADVISORS LLCDirectorAWARD8,912,655$5.61$50.0M
Feb 4, 2026Brooks GabrielChief Medical OfficerSELL12,616$6.44$81.3K
Feb 4, 2026Herzich PaulChief Technology OfficerSELL10,905$6.44$70.2K
Feb 4, 2026Cumbo AlexanderPresident and CEOSELL48,913$6.44$315.1K
Feb 4, 2026Tan KevinCFO & TreasurerSELL14,783$6.44$95.2K
Feb 4, 2026Hanrahan JessieChief Regulatory OfficerSELL12,348$6.44$79.5K
Feb 4, 2026Howton David TChief Operating OfficerSELL18,894$6.44$121.7K
Feb 4, 2026Ganot IlanDirectorSELL7,205$6.44$46.4K
Feb 2, 2026Brooks GabrielChief Medical OfficerSELL28,335$6.44$182.4K
Feb 2, 2026Tan KevinCFO & TreasurerSELL26,837$6.44$172.7K
Feb 2, 2026Cumbo AlexanderPresident and CEOSELL80,258$6.44$516.6K
Feb 2, 2026Herzich PaulChief Technology OfficerSELL26,250$6.44$169.0K
Feb 2, 2026Howton David TChief Operating OfficerSELL37,771$6.44$243.1K
Feb 2, 2026Hanrahan JessieChief Regulatory OfficerSELL26,535$6.44$170.8K
Jan 31, 2026Ganot IlanDirectorEXERCISE15,000——
Jan 31, 2026Brooks GabrielChief Medical OfficerEXERCISE28,225——
Jan 31, 2026Tan KevinCFO & TreasurerEXERCISE33,075——
Jan 31, 2026Cumbo AlexanderPresident and CEOEXERCISE100,400——
Jan 31, 2026Herzich PaulChief Technology OfficerEXERCISE24,675——
Jan 31, 2026Howton David TChief Operating OfficerEXERCISE42,275——
Jan 31, 2026Hanrahan JessieChief Regulatory OfficerEXERCISE27,625——
Jan 29, 2026Howton David TChief Operating OfficerAWARD79,341——
Jan 29, 2026Hanrahan JessieChief Regulatory OfficerAWARD54,925——
Jan 29, 2026Brooks GabrielChief Medical OfficerAWARD58,847——
Jan 29, 2026Cumbo AlexanderPresident and CEOAWARD169,401——
Jan 29, 2026Herzich PaulChief Technology OfficerAWARD54,925——
Jan 29, 2026Tan KevinCFO & TreasurerAWARD56,647——
Jan 29, 2026Ganot IlanDirectorAWARD70,900——
Jan 29, 2026Ganot IlanDirectorAWARD35,450——
Jan 29, 2026Brooks GabrielChief Medical OfficerEXERCISE58,847——
Jan 29, 2026Brooks GabrielChief Medical OfficerAWARD207,450——
Jan 29, 2026Brooks GabrielChief Medical OfficerAWARD103,750——
Jan 29, 2026Tan KevinCFO & TreasurerEXERCISE56,646——
Jan 29, 2026Tan KevinCFO & TreasurerAWARD187,000——
Jan 29, 2026Tan KevinCFO & TreasurerAWARD93,500——
Jan 29, 2026Cumbo AlexanderPresident and CEOEXERCISE169,401——
Jan 29, 2026Cumbo AlexanderPresident and CEOAWARD509,850——
Jan 29, 2026Cumbo AlexanderPresident and CEOAWARD254,900——
Jan 29, 2026Herzich PaulChief Technology OfficerEXERCISE54,925——
Jan 29, 2026Herzich PaulChief Technology OfficerAWARD170,000——
5 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 2 neutral. Avg impact: 5.2/10.
BEARISH PRESS-RELEASE 6/10
Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net
May 12, 2026
NEUTRAL DEFA14A 3/10
Solid Biosciences is holding its 2026 annual meeting with several key proposals, including the ratif
Apr 23, 2026
NEUTRAL 8-K 2/10
Solid Biosciences Inc. announced a board seat reclassification for director Ilan Ganot, who resigned
Apr 10, 2026
BEARISH EFFECT 7/10
Solid Biosciences Inc. has two S-3 shelf registration statements that became effective on March 31,
Apr 1, 2026
BULLISH 8-K 8/10
Solid Biosciences announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-
Mar 12, 2026
BULLISH 7/10
Solid Biosciences dosed the first participant in its Phase 3 IMPACT DUCHENNE trial for SGT-003, a ge
May 7, 2026
BULLISH 8/10
Solid Biosciences reported financial results for Q4 and full year 2025, highlighted by strong pipeli
Mar 19, 2026
BULLISH 8/10
Solid Biosciences reported updated positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial f
Mar 11, 2026
NEUTRAL 6/10
Solid Biosciences (SLDB) announced a $240 million private placement through the sale of common stock
Mar 6, 2026
NEUTRAL 3/10
Solid Biosciences granted 17,600 restricted stock units (RSUs) to a newly hired employee as an induc
Mar 2, 2026
Current analyst consensus: Strong Buy (95% buy). Based on 20 analysts: 8 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$17.38 mean target +143.5% upside Strong Buy (1.29)
$11.00 Low $26.00 High
MetricValue
Current Price$7.14
Target Low$11.00
Target Mean$17.38
Target Median$16.00
Target High$26.00
# Analysts13
RecommendationStrong Buy (1.29)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.46 $-0.56 $-0.36 -10.3% — 2↑ 9↓ $0.0B 0.0% 13
Next Q
2026-09-30
 $-0.48 $-0.57 $-0.39 1.0% — 2↑ 9↓ $0.0B 0.0% 13
Current FY
2026-12-31
 $-1.96 $-2.51 $-1.67 1.7% — 1↑ 12↓ $0.0B 0.0% 13
Next FY
2027-12-31
 $-1.96 $-2.33 $-1.56 -0.0% — 2↑ 10↓ $0.0B 0.0% 12

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.463
7d ago$-0.468+0.004
30d ago$0.000-0.463
60d ago$-0.409-0.054
90d ago$-0.520+0.057
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jun 3, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
May 18, 2026 Wedbush REITERATE Outperform Outperform
May 13, 2026 Wedbush MAINTAIN Outperform Outperform
May 13, 2026 Piper Sandler MAINTAIN Overweight Overweight
Mar 25, 2026 JP Morgan MAINTAIN Overweight Overweight
Mar 23, 2026 HC Wainwright & Co. REITERATE Buy Buy
Mar 20, 2026 Guggenheim INITIATE — Buy
Mar 20, 2026 Chardan Capital MAINTAIN Buy Buy
Mar 20, 2026 Needham REITERATE Buy Buy
Mar 12, 2026 Wedbush MAINTAIN Outperform Outperform
Mar 12, 2026 Chardan Capital MAINTAIN Buy Buy
Mar 11, 2026 Wedbush REITERATE Outperform Outperform
Feb 9, 2026 Needham REITERATE Buy Buy
Jan 14, 2026 Needham REITERATE Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 202681110095%
May 1, 202681110095%
Apr 1, 202681110095%
Mar 1, 202671110095%
Feb 1, 202671110095%
Jan 1, 202671210095%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 1, 2026
other
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing p
Jun 1, 2026
other
Solid Biosciences to Participate at Upcoming Investor Conferences
<p>CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company d
May 14, 2026
short_volume
Short Volume: SLDB — 57.9% short (0.4M / 0.7M)
Short: 427,277 | Exempt: 842 | TRF Vol: 737,730 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
SLDB Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
earnings
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
<p align="center"><em>-</em><strong><em> Duchenne (SGT-003):</em></strong><em> First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial,
May 7, 2026
fda
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
<p align="center"><em>- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-
May 1, 2026
other
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>CHARLESTOWN, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing pr
Apr 14, 2026
short_volume
Short Volume: SLDB — 66.8% short (0.6M / 0.8M)
Short: 560,888 | Exempt: 200 | TRF Vol: 840,181 | Short Ratio: 66.8% | Off-exchange volume (dark pool + OTC)
Mar 19, 2026
earnings
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
<p align="center"><em>- <strong>Duchenne (SGT-003):</strong> Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting
Mar 11, 2026
fda
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial
<p align="center"><em>- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date -</em></p>
Mar 6, 2026
offering
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
<p>CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision geneti
Mar 6, 2026
other
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
<p align="justify">CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing
Mar 4, 2026
earnings_calendar
SLDB Q4 2025 Earnings After Market Close — 2026-03-04
Mar 2, 2026
regulatory
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>CHARLESTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing